Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.

Molecular cancer therapeutics - 1 Dec 2015

Mazor Ronit, Zhang Jingli, Xiang Laiman, Addissie Selamawit, Awuah Prince, Beers Richard, Hassan Raffit, Pastan Ira

Abstract excerpt

SS1P is a recombinant immunotoxin (RIT) that targets mesothelin. It consists of an antimesothelin Fv fused to a portion of Pseudomonas exotoxin A. In clinical studies, it has produced dramatic responses in patients with advanced mesothelioma, when combined with immunosuppressive therapy so that several treatment cycles could be given. Otherwise its activity is limited by its immunogenicity. In this work, we...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to ADP Ribose Transferases
Share to Bacterial Toxins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Epitopes, T-Lymphocyte

Share to Exotoxins

Share to GPI-Linked Proteins

Share to Immunogenetic Phenomena

Share to Mesothelioma

Share to Xenograft Model Antitumor Assays

Source

Open in PubMed Open full text

Identifiers

PMID: 26443804
DOI: 10.1158/1535-7163.MCT-15-0532
PMCID: PMC4674367

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Recombinant Immunotoxin with T-cell Epitope Mutations That Greatly Reduce Immunogenicity for Treatment of Mesothelin-Expressing Tumors.PMID 26443804Read ↗

Dual B- and T-cell de-immunization of recombinant immunotoxin targeting mesothelin with high cytotoxic activity.Semantic proximity Read ↗

Targeted therapy against human lung cancer in nude mice by high-affinity recombinant antimesothelin single-chain Fv immunotoxin.Semantic proximity Read ↗

Reduced Shedding of Surface Mesothelin Improves Efficacy of Mesothelin-Targeting Recombinant Immunotoxins.Semantic proximity Read ↗

Anti-tumor activity of K1-LysPE38QQR, an immunotoxin targeting mesothelin, a cell-surface antigen overexpressed in ovarian cancer and malignant mesothelioma.Semantic proximity Read ↗

MesothelinSemantic proximity Read ↗

Immunotoxins with decreased immunogenicity and improved activity.Semantic proximity Read ↗

Advancing pancreatic cancer therapy by mesothelin-specific nanobody conjugationSemantic proximity Read ↗

A recombinant immunotoxin engineered for increased stability by adding a disulfide bond has decreased immunogenicity.Semantic proximity Read ↗

Removal of B-cell epitopes for decreasing immunogenicity in recombinant immunotoxin against B-cell malignancies.Semantic proximity Read ↗

Recombinant immunotoxin for cancer treatment with low immunogenicity by identification and silencing of human T-cell epitopesSemantic proximity Read ↗

Identification and elimination of an immunodominant T-cell epitope in recombinant immunotoxins based on Pseudomonas exotoxin A.Semantic proximity Read ↗

Immunoconjugates in the management of hairy cell leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.